GLP1R and diabetes mellitus: The proportions of patients using GLAs with demonstrated CV benefit may change with the implementation and influence of recent updates to diabetes/cardiology guidelines that now recommend a GLP-1 RA or SGLT2i with demonstrated CV benefit as first- or second-line GLA in people with T2D and established CVD or at high/very high CVD risk [5–7].